Description

CILAHEART 10 MG (1X15)

Indications

CILAHEART 10 MG is primarily indicated for the management of hypertension and the treatment of heart failure. It is often prescribed to patients who require blood pressure control to reduce the risk of cardiovascular events, such as stroke and myocardial infarction. Additionally, CILAHEART may be utilized in patients with specific heart conditions to improve heart function and overall quality of life.

Mechanism of Action

The active ingredient in CILAHEART is Cilnidipine, a calcium channel blocker that acts on both L-type and N-type calcium channels. By inhibiting these channels, Cilnidipine reduces the influx of calcium ions into vascular smooth muscle and cardiac muscle cells. This action leads to vasodilation, which decreases peripheral vascular resistance and subsequently lowers blood pressure. Furthermore, the N-type calcium channel blockade contributes to a reduction in sympathetic nervous system activity, which can also play a role in managing heart failure symptoms.

Pharmacological Properties

CILAHEART exhibits several pharmacological properties that make it effective in treating cardiovascular conditions. It has a rapid onset of action, typically within 1 hour of administration, and its antihypertensive effects can last for up to 24 hours. The bioavailability of Cilnidipine is approximately 60%, and it is extensively metabolized in the liver. The elimination half-life of the drug is around 8 to 12 hours, allowing for once-daily dosing in most patients. CILAHEART is also known for its favorable side effect profile compared to other calcium channel blockers, making it a preferred choice for many clinicians.

Contraindications

CILAHEART should not be used in patients with known hypersensitivity to Cilnidipine or any of the excipients in the formulation. It is contraindicated in individuals with severe hypotension, cardiogenic shock, or significant aortic stenosis. Additionally, caution should be exercised when prescribing CILAHEART to patients with hepatic impairment or severe renal dysfunction, as these conditions may affect the drug’s metabolism and excretion.

Side Effects

Like any medication, CILAHEART may cause side effects, although not everyone experiences them. Common side effects include headache, dizziness, flushing, and peripheral edema. Some patients may experience gastrointestinal disturbances such as nausea or constipation. In rare cases, more serious side effects may occur, including hypotension, bradycardia, or allergic reactions. Patients should be advised to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of CILAHEART is 10 mg once daily. Depending on the patient’s response and tolerability, the dosage may be adjusted, with a maximum dose of 20 mg per day. It is important to take CILAHEART at the same time each day to maintain consistent blood levels of the medication. The tablets should be swallowed whole with water and can be taken with or without food. Patients should be monitored regularly for blood pressure and heart rate to ensure optimal therapeutic outcomes.

Interactions

CILAHEART may interact with other medications, which can affect its efficacy or increase the risk of adverse effects. Co-administration with other antihypertensive agents may lead to additive hypotensive effects. Caution is advised when using CILAHEART with medications that affect liver enzymes, as they may alter the metabolism of Cilnidipine. Additionally, the use of CILAHEART with grapefruit juice should be avoided, as it may increase the plasma concentration of the drug, leading to enhanced effects and potential toxicity.

Precautions

Before starting treatment with CILAHEART, a thorough medical history and physical examination should be conducted. Special precautions should be taken in patients with existing cardiovascular conditions, such as heart failure or arrhythmias. Regular monitoring of blood pressure and heart rate is essential, particularly during the initial stages of treatment or when adjusting the dosage. Patients should be advised to avoid sudden discontinuation of the medication, as this may lead to rebound hypertension. Furthermore, caution should be exercised in elderly patients or those with multiple comorbidities, as they may be at higher risk for adverse effects.

Clinical Studies

Several clinical studies have evaluated the efficacy and safety of CILAHEART in the management of hypertension and heart failure. In a randomized controlled trial, patients treated with Cilnidipine demonstrated significant reductions in systolic and diastolic blood pressure compared to placebo. Furthermore, data from long-term studies indicated that CILAHEART not only effectively controlled blood pressure but also improved left ventricular function in patients with heart failure. These findings support the use of CILAHEART as a valuable therapeutic option in managing cardiovascular diseases.

Conclusion

CILAHEART 10 MG is a well-established medication for the treatment of hypertension and heart failure. Its dual mechanism of action, favorable pharmacokinetic profile, and tolerability make it an effective choice for many patients. However, as with any medication, it is essential for healthcare providers to consider individual patient characteristics and potential drug interactions when prescribing CILAHEART. Ongoing monitoring and patient education are crucial to ensure safe and effective treatment outcomes.